Compare Enphase Energy Inc (ENPH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Enphase Energy Inc trades at $40.9 (market cap $5.59B), while State Street SPDR S&P Biotech ETF trades at $159.4. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.
| ENPH | XBI | |
|---|---|---|
Market Cap | $5.59B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $72.33 | $164.28 |
52-Week Low | $26.12 | $86.92 |
Enterprise Value | $5.23B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $40.86, down 0.15% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings that matched estimates but missed revenue expectations, with revenue declining 19.6% year-over-year. Recent news highlights product expansion including IQ Battery 10C support for third-party systems and reinforced U.S. manufacturing commitments across residential, commercial and AI infrastructure segments.
While analyst consensus remains cautiously optimistic with a $45.37 price target, ENPH faces headwinds from cyclical residential solar demand and competitive pressures. The stock offers potential upside if the company can execute on its storage-led recovery strategy and capitalize on AI data center opportunities, though investors should monitor execution risks and market volatility in the solar sector.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
